$3.9 billion was wiped off Sepracor's market capitalization as investors called into question the entire utility of single enantiomers as a means of improving drugs and managing product life cycles.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果一些您可能无法访问的结果已被隐去。
显示无法访问的结果